Abstract:e15527 Background: BRAF mutations are present in 5-10% of metastatic colorectal cancers (mCRCs). Patients with mCRC whose tumors harbor BRAF V600 mutation generally respond poorly to standard chemotherapy. Treatment with BRAF inhibitors has been shown to improve outcomes, whereas the resistance develops through undefined mechanisms. Therefore, it is imperative to accurately comprehend the genomic profiling of resistance mechanisms to BRAF inhibitors in mCRC for exploring its clinical treatment strategies. Methods: We analyzed next-generation sequencing results in 520 cancer-associated genes for 22 patients who had BRAF V600E mutant mCRC in order to characterize genomic predictors of treatment outcome and track the acquired resistance (AR) mechanisms during the vemurafenib/dabrafenib/encorafenib treatment in combination with cetuximab +/- trametinib. The median age of the patients was 61 years old, 54.5% were male, 54.5% had right-sided mCRC, and 81.8% received one or more prior chemotherapy lines. Tissue and/or plasma samples were collected at baseline (prior to anti-BRAF treatment) and upon disease progression (PD). Objective tumor responses were radiologically assessed every 6 weeks according to RECIST v1. 1. Results: By Feb 2021, treatment had been discontinued in 15 (63.2%) of the patients due to disease progression, while the other 7 cases were still under treatment. The median PFS (mPFS) for all patients was 4.5 months. The overall response rate was 32%, and the disease control rate was 86%. In addition to BRAF V600E, the most common concomitant mutations were identified in TP53 (20/22), RNF43 (8/22), LRP18 (7/22), APC (7/22) and PIK3CA (5/22). Patients with baseline alterations in RNF43 (n = 8; p = 0.0466), or RECQL4 (n = 4; p = 0.0406) had significantly longer PFS than their respective wild type counterparts. In contrast, baseline alterations in PPP2R2A (n = 3; p = 0.0131), RUNX1T1 (n = 3; p = 0.0147), and receptor tyrosine kinase (RTK) signaling pathway genes (n = 6; p = 0.0057) were each significantly associated with shorter PFS. Among the 15 patients whose disease progressed, 9 were identified with newly developed AR mutations in PD tumor or plasma samples. MET amplification was the most common AR mechanism (n = 4) followed by BRAF amplification, KRAS, NRAS mutations (n = 3 each), and MAP2K1, PIK3R1 mutations (n = 1 each). Q61 substitution was the most dominant form for both KRAS and NRAS AR mutations (83%, 5/6). In terms of signaling pathway, MAPK (67%, 6/9) and RTK (44%, 4/9) pathway alterations were most frequently observed. Conclusions: Our study illustrated the landscape of genetic alterations in patients with BRAF V600E mutant mCRC upon BRAF inhibitor treatment, which could be critical to predict responses to BRAF inhibitors and guide personalized clinical decision-making after disease progression.

RAS/BRAF Status Determines Treatment Efficacy and Prognosis of Metastatic Colorectal Cancer: A Real Word Analysis of 1002 Consecutive Cases

Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases

Correction To: Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Real‐world Treatment and Outcomes of Patients with Metastatic BRAF Mutant Colorectal Cancer

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

An Analysis Of Relationship Between Ras Mutations And Prognosis Of Primary Tumour Resection For Metastatic Colorectal Cancer Patients

The Optimal First-Line Treatment for Patients with Left-Sided RAS Wild-Type Metastatic Colorectal Cancer: Double-drug Regimen or Triple-Drug Regimen Therapy

Clinicopathologic Features and Treatment Efficacy of Chinese Patients with BRAF -Mutated Metastatic Colorectal Cancer: a Retrospective Observational Study

Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation: A Multicenter Real-World Study in China.

Clinicopathologic features and impact of metastasectomy in patients with BRAF-mutant metastatic colorectal cancer.

Prognostic Role Of Braf Mutation In Stage Ii/Iii Colorectal Cancer Receiving Curative Resection And Adjuvant Chemotherapy: A Meta-Analysis Based On Randomized Clinical Trials

Prognostic Impact of KRAS and BRAF Mutations in Patients Who Underwent Simultaneous Resection for Initially Resectable Colorectal Liver Metastases

Reclassification of RAS/BRAF allele mutations predicts the survival benefit of triplet chemotherapy in metastatic colorectal cancer

Clinical/molecular features and prognostic significance of RAS mutant-low versus RAS mutant-high in patients with metastatic colorectal cancer.

Association of various RAS codon mutations and prognostic outcomes of patients with colorectal liver metastases after hepatectomy

Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.

RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy

Clinicopathologic Features and Prognostic Value of KRAS, NRAS and BRAF Mutations and DNA Mismatch Repair Status: A Single‐center Retrospective Study of 1,834 Chinese Patients with Stage I–IV Colorectal Cancer

Genomic profiles of BRAF inhibitor resistance mechanisms in metastatic colorectal cancer.

The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis